ATE397444T1 - Analgetische zusammensetzungen die nmda- rezeptorantagonisten und benzalkoniumclorid enthalten - Google Patents
Analgetische zusammensetzungen die nmda- rezeptorantagonisten und benzalkoniumclorid enthaltenInfo
- Publication number
- ATE397444T1 ATE397444T1 AT03759633T AT03759633T ATE397444T1 AT E397444 T1 ATE397444 T1 AT E397444T1 AT 03759633 T AT03759633 T AT 03759633T AT 03759633 T AT03759633 T AT 03759633T AT E397444 T1 ATE397444 T1 AT E397444T1
- Authority
- AT
- Austria
- Prior art keywords
- nmda receptor
- receptor antagonists
- benzalkonium
- cloriide
- compositions containing
- Prior art date
Links
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000000202 analgesic effect Effects 0.000 title 1
- 229960001716 benzalkonium Drugs 0.000 title 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 title 1
- 239000003755 preservative agent Substances 0.000 abstract 2
- 230000002335 preservative effect Effects 0.000 abstract 2
- 206010002091 Anaesthesia Diseases 0.000 abstract 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical group C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 abstract 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 abstract 1
- 206010029350 Neurotoxicity Diseases 0.000 abstract 1
- 206010044221 Toxic encephalopathy Diseases 0.000 abstract 1
- 230000037005 anaesthesia Effects 0.000 abstract 1
- 230000036592 analgesia Effects 0.000 abstract 1
- 229960000686 benzalkonium chloride Drugs 0.000 abstract 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical group [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 abstract 1
- 229960003299 ketamine Drugs 0.000 abstract 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 abstract 1
- 230000007135 neurotoxicity Effects 0.000 abstract 1
- 231100000228 neurotoxicity Toxicity 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/256,283 US7273889B2 (en) | 2002-09-25 | 2002-09-25 | NMDA receptor antagonist formulation with reduced neurotoxicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE397444T1 true ATE397444T1 (de) | 2008-06-15 |
Family
ID=31993505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03759633T ATE397444T1 (de) | 2002-09-25 | 2003-09-25 | Analgetische zusammensetzungen die nmda- rezeptorantagonisten und benzalkoniumclorid enthalten |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US7273889B2 (de) |
| EP (1) | EP1562566B1 (de) |
| AT (1) | ATE397444T1 (de) |
| AU (1) | AU2003275357A1 (de) |
| DE (1) | DE60321479D1 (de) |
| DK (1) | DK1562566T3 (de) |
| ES (1) | ES2307975T3 (de) |
| PT (1) | PT1562566E (de) |
| SI (1) | SI1562566T1 (de) |
| WO (1) | WO2004028522A1 (de) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| US20050025018A1 (en) | 2003-07-28 | 2005-02-03 | Han-Wen Hsu | Apparatus and method for automatic power control |
| US7994686B2 (en) * | 2004-06-14 | 2011-08-09 | Massachusetts Institute Of Technology | Electrochemical methods, devices, and structures |
| US7999435B2 (en) * | 2004-06-14 | 2011-08-16 | Massachusetts Institute Of Technology | Electrochemical actuator |
| CA2570092A1 (en) | 2004-06-14 | 2005-12-29 | Massachusetts Institute Of Technology | Electrochemical methods, devices, and structures |
| US8247946B2 (en) | 2004-06-14 | 2012-08-21 | Massachusetts Institute Of Technology | Electrochemical actuator |
| US7872396B2 (en) | 2004-06-14 | 2011-01-18 | Massachusetts Institute Of Technology | Electrochemical actuator |
| CN101466364A (zh) * | 2006-03-22 | 2009-06-24 | 纽约大学西奈山医学院 | 鼻内施用氯胺酮治疗抑郁症 |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| JP5930573B2 (ja) | 2007-03-01 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤の新規使用 |
| JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
| JP2010525081A (ja) * | 2007-04-26 | 2010-07-22 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 重水素標識ケタミン |
| WO2009015389A2 (en) * | 2007-07-26 | 2009-01-29 | Entra Pharmaceuticals Inc. | Skin-patch pump comprising a changing-volume electrochemical actuator |
| BRPI0918868B8 (pt) | 2008-09-18 | 2021-05-25 | Naurex Inc | compostos moduladores do receptor de nmda e composições compreendendo os mesmos |
| DK3006024T3 (da) | 2009-01-20 | 2019-06-03 | Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct | Benzoesyre eller salte deraf til forstærkning af aktiviteten af et neurofarmaceutisk lægemiddel |
| PL2475428T3 (pl) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| CA2789331C (en) | 2010-02-11 | 2017-11-07 | Northwestern University | Secondary structure stabilized nmda receptor modulators and uses thereof |
| EP2542549B1 (de) | 2010-03-03 | 2016-05-11 | Probiodrug AG | Glutaminylcyclase-hemmer |
| US8269019B2 (en) | 2010-03-10 | 2012-09-18 | Probiodrug Ag | Inhibitors |
| US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
| WO2011140359A2 (en) | 2010-05-05 | 2011-11-10 | Springleaf Therapeutics, Inc. | Systems and methods for delivering a therapeutic agent |
| CA2796774C (en) * | 2010-06-15 | 2020-06-02 | Gruenenthal Gmbh | Pharmaceutical combination for the treatment of pain |
| WO2012083174A2 (en) | 2010-12-17 | 2012-06-21 | Massachusetts Institute Of Technology | Electrochemical actuators |
| US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
| US9073819B2 (en) | 2011-06-30 | 2015-07-07 | University Of South Florida | Compositions, methods of use, and methods of treatment |
| CN104519878A (zh) * | 2012-03-12 | 2015-04-15 | 詹森药业有限公司 | 用于治疗顽固性或难治性抑郁症的艾氯胺酮 |
| AU2014209028C1 (en) * | 2013-01-28 | 2019-08-29 | Hector L. Lopez | Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor |
| WO2014120800A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| CA2898861C (en) | 2013-01-29 | 2021-07-20 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| PH12015501596B1 (en) | 2013-01-29 | 2023-12-06 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof |
| CN105026401A (zh) | 2013-01-29 | 2015-11-04 | 诺雷克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
| CA2898863A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| MX371392B (es) | 2013-03-15 | 2020-01-28 | Janssen Pharmaceutica Nv | Composicion farmaceutica de clorhidrato de s-ketamina. |
| DK2983787T3 (da) | 2013-04-12 | 2020-01-06 | Icahn School Med Mount Sinai | Fremgangsmåde til behandling af posttraumatisk stresssygdom |
| EP3964203A1 (de) | 2013-09-13 | 2022-03-09 | National University Corporation Chiba University | R-ketamin und dessen salze als medikament |
| JP6545788B2 (ja) | 2014-08-13 | 2019-07-17 | ヤンセン ファーマシューティカ エヌ．ベー． | うつ病の治療方法 |
| US20160074340A1 (en) | 2014-09-15 | 2016-03-17 | Janssen Pharmaceutica Nv | VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| EP3297620A4 (de) | 2015-06-27 | 2019-01-09 | Shenox Pharmaceuticals, LLC | Transdermales abgabesystem für ketamin |
| EA201892657A1 (ru) | 2016-05-19 | 2019-05-31 | Аптиникс Инк. | Спиролактамовые модуляторы nmda-рецептора и их применение |
| WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| EP3468946A4 (de) | 2016-06-13 | 2020-02-12 | Syneurx International (Taiwan) Corp. | Co-kristalle von lithium-benzoat und verwendungen davon |
| MX2018015397A (es) | 2016-06-13 | 2019-08-16 | Syneurx Int Taiwan Corp | Co-cristales de benzoato de sodio y sus usos. |
| IL286107B2 (en) | 2016-08-01 | 2024-09-01 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and usesthereof |
| CA3031537A1 (en) | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| WO2018026792A1 (en) | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof |
| CN109843889B (zh) | 2016-08-01 | 2022-03-15 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda调节剂和使用其的方法 |
| US10961189B2 (en) | 2016-08-01 | 2021-03-30 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| US10336679B2 (en) | 2016-10-24 | 2019-07-02 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US11369579B2 (en) | 2016-10-24 | 2022-06-28 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| US10098861B1 (en) | 2017-10-24 | 2018-10-16 | Syneurx International (Taiwan) Corp. | Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof |
| US11622948B2 (en) | 2017-11-09 | 2023-04-11 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| US11491120B2 (en) | 2017-11-09 | 2022-11-08 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders in females |
| KR20200113197A (ko) | 2017-12-22 | 2020-10-06 | 얀센 파마슈티칼즈, 인코포레이티드 | 우울증 치료를 위한 에스케타민 |
| US11578072B2 (en) | 2018-01-31 | 2023-02-14 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| EP3753557B1 (de) | 2018-02-15 | 2025-11-05 | National University Corporation Chiba University | Präventives oder therapeutisches mittel und pharmazeutische zusammensetzung für entzündungserkrankungen oder knochenerkrankungen |
| CN112533595A (zh) | 2018-05-04 | 2021-03-19 | 感知神经科学公司 | 治疗物质滥用的方法 |
| US11154537B2 (en) | 2018-08-10 | 2021-10-26 | Eleusis Therapeutics Us, Inc. | Method of treatment for ketamine infusion |
| EP3934632A4 (de) | 2019-03-05 | 2022-11-23 | Janssen Pharmaceuticals, Inc. | Esketamin zur behandlung von depression |
| US11160799B2 (en) * | 2019-10-22 | 2021-11-02 | Cessatech A/S | Pediatric combination |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
| CA3164022A1 (en) | 2020-01-22 | 2021-07-29 | Raj Mehra | Use of intranasal racemic ketamine to treat suicidality and major depression |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3760077A (en) * | 1969-02-18 | 1973-09-18 | Cutter Lab | Injectable compositions of the (plus)-optical isomer of the alpha racemate of 2-(2-ethyl-2-phenyl-1, -dioxolan-4-yl)piperidine and their use |
| CH535201A (de) | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
| US4017619A (en) * | 1973-10-26 | 1977-04-12 | Burnap Raymond W | Anesthetic and sedative composition |
| EP0424179A3 (en) * | 1989-10-20 | 1991-12-27 | John William Olney | Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration |
| GB9020544D0 (en) * | 1990-09-20 | 1990-10-31 | Sandoz Ltd | Improvements in or relating to organic compounds |
| US5250732A (en) * | 1991-07-18 | 1993-10-05 | Genentech, Inc. | Ketamine analogues for treatment of thrombocytopenia |
| US6350784B1 (en) * | 1996-02-12 | 2002-02-26 | Meryl J. Squires | Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases |
| US5854217A (en) * | 1992-09-28 | 1998-12-29 | Bearsden Bio, Inc. | Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function |
| US5321012A (en) * | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
| US5352683A (en) * | 1993-03-05 | 1994-10-04 | Virginia Commonwealth University Medical College Of Virginia | Method for the treatment of chronic pain |
| RU2053300C1 (ru) * | 1993-12-17 | 1996-01-27 | Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов | Штамм бактерий rhodococcus rhodochrous - продуцент нитрилгидратазы |
| US5897858A (en) * | 1994-02-03 | 1999-04-27 | Schering-Plough Healthcare Products, Inc. | Nasal spray compositions exhibiting increased retention in the nasal cavity |
| US5543434A (en) * | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
| US5683709A (en) * | 1994-05-05 | 1997-11-04 | Ciba Vision Corporation | Poly(benzalkonium salt) as an anti-microbial agent for aqueous drug compositions |
| US5604244A (en) * | 1995-06-07 | 1997-02-18 | Alcon Laboratories, Inc. | Intraocular irrigating solution containing a polyamine antagonist |
| US6194415B1 (en) * | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| US6197830B1 (en) * | 1995-09-22 | 2001-03-06 | Bruce M. Frome | Method for achieving relief from sympathetically mediated pain |
| US6441047B2 (en) * | 1995-11-17 | 2002-08-27 | Alcon Manufacturing Ltd.. | Combination therapy for treating glaucoma |
| DE19601782A1 (de) * | 1996-01-19 | 1997-07-24 | Merck Patent Gmbh | Chinolin-2-(1H)one |
| US5688830A (en) * | 1996-01-25 | 1997-11-18 | Syntex (U.S.A.) Inc. | Treatment of neuropathic pain |
| US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| US6576636B2 (en) * | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
| NZ332762A (en) * | 1996-07-24 | 2000-09-29 | Warner Lambert Co | Isobutylgaba and its derivatives for the treatment of pain |
| US6248789B1 (en) * | 1996-08-29 | 2001-06-19 | Stuart L. Weg | Administration of ketamine to manage pain and to reduce drug dependency |
| US5919826A (en) * | 1996-10-24 | 1999-07-06 | Algos Pharmaceutical Corporation | Method of alleviating pain |
| US20020039594A1 (en) * | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
| US6124282A (en) * | 1997-05-22 | 2000-09-26 | Sellers; Edward M. | Drug formulations |
| US5817699A (en) * | 1997-05-30 | 1998-10-06 | Flores; John A. | Process for the preparation of ketamine ointment |
| US6329429B1 (en) * | 1997-06-25 | 2001-12-11 | Warner-Lambert Company | Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases |
| FR2772271B1 (fr) * | 1997-12-11 | 2000-09-01 | Union Pharma Scient Appl | Nouvelle association pharmaceutique a activite analgesique |
| EP1126850A4 (de) | 1998-10-27 | 2003-01-15 | Alcon Lab Inc | Behandlung von retinalerkrankungen |
| AU1602100A (en) * | 1998-11-25 | 2000-06-13 | Warner-Lambert Company | Improved gamma amino butyric acid analogs |
| AU2056700A (en) * | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity |
| US6200990B1 (en) * | 1998-12-21 | 2001-03-13 | Alcon Laboratories, Inc. | Neuroprotective agents having antioxidant and NMDA antagonist activity |
| US6017961A (en) * | 1999-07-08 | 2000-01-25 | Flores; John Anthony | Ketamine and n-butyl-p-aminobezoate in PLO |
| US7160890B2 (en) * | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| AP2002002565A0 (en) * | 1999-12-28 | 2002-06-30 | Pfizer Prod Inc | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases. |
| CA2407683C (en) * | 2000-04-28 | 2010-04-13 | Memorial Sloan-Kettering Cancer Center | Topical anesthetic/opioid formulations and uses thereof |
| US20020013331A1 (en) * | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
| US6787532B2 (en) * | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
| US6902734B2 (en) * | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
| US6878751B1 (en) * | 2000-10-19 | 2005-04-12 | Imperial College Of Science Technology And Medicine | Administration of resveratrol to treat inflammatory respiratory disorders |
| MXPA03004652A (es) * | 2000-12-21 | 2003-09-05 | Warner Lambert Co | Derivados de piperidina como antagonistas selectivos de subtipo de n-metil-d-aspartato. |
| US6649187B2 (en) * | 2001-02-16 | 2003-11-18 | Bristol-Myers Squibb Pharma Company | Use of polyalkylamine polymers in controlled release devices |
| US20020198209A1 (en) * | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
| EP1423175B1 (de) * | 2001-08-08 | 2013-10-02 | Brown University Research Foundation | Verfahren zur mikronisierung von hydrophoben arzneistoffen |
| US6638981B2 (en) * | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
| US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| US20040266808A1 (en) * | 2003-06-27 | 2004-12-30 | Kamen Barton A. | Treatment of antifolate neurotoxicity |
| US6989445B2 (en) * | 2003-12-15 | 2006-01-24 | Alcon, Inc. | Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma |
-
2002
- 2002-09-25 US US10/256,283 patent/US7273889B2/en not_active Expired - Lifetime
-
2003
- 2003-09-25 DK DK03759633T patent/DK1562566T3/da active
- 2003-09-25 SI SI200331297T patent/SI1562566T1/sl unknown
- 2003-09-25 EP EP03759633A patent/EP1562566B1/de not_active Expired - Lifetime
- 2003-09-25 PT PT03759633T patent/PT1562566E/pt unknown
- 2003-09-25 AU AU2003275357A patent/AU2003275357A1/en not_active Abandoned
- 2003-09-25 WO PCT/US2003/031073 patent/WO2004028522A1/en not_active Ceased
- 2003-09-25 DE DE60321479T patent/DE60321479D1/de not_active Expired - Fee Related
- 2003-09-25 ES ES03759633T patent/ES2307975T3/es not_active Expired - Lifetime
- 2003-09-25 AT AT03759633T patent/ATE397444T1/de not_active IP Right Cessation
- 2003-12-05 US US10/729,869 patent/US20040138298A1/en not_active Abandoned
-
2007
- 2007-08-16 US US11/839,985 patent/US20080041367A1/en not_active Abandoned
-
2014
- 2014-02-21 US US14/186,765 patent/US20140171514A1/en not_active Abandoned
-
2015
- 2015-03-23 US US14/666,077 patent/US20160000733A1/en not_active Abandoned
-
2016
- 2016-02-29 US US15/056,519 patent/US20160175266A1/en not_active Abandoned
-
2021
- 2021-06-01 US US17/335,407 patent/US20220054435A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1562566B1 (de) | 2008-06-04 |
| SI1562566T1 (sl) | 2009-02-28 |
| DK1562566T3 (da) | 2008-09-22 |
| US20160000733A1 (en) | 2016-01-07 |
| US20040138298A1 (en) | 2004-07-15 |
| US20160175266A1 (en) | 2016-06-23 |
| US7273889B2 (en) | 2007-09-25 |
| US20140171514A1 (en) | 2014-06-19 |
| US20080041367A1 (en) | 2008-02-21 |
| WO2004028522A1 (en) | 2004-04-08 |
| DE60321479D1 (de) | 2008-07-17 |
| PT1562566E (pt) | 2008-09-11 |
| AU2003275357A1 (en) | 2004-04-19 |
| EP1562566A1 (de) | 2005-08-17 |
| US20220054435A1 (en) | 2022-02-24 |
| US20040059003A1 (en) | 2004-03-25 |
| ES2307975T3 (es) | 2008-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE397444T1 (de) | Analgetische zusammensetzungen die nmda- rezeptorantagonisten und benzalkoniumclorid enthalten | |
| IS7142A (is) | Lyfjasamsetningar, sem innihalda morfíngerandaefni, ásamt losanlegu en hömdu mótlyfi | |
| PT1041987E (pt) | Forma farmaceutica de dosagem oral, compreendendo uma combinacao de um agonista de opioide e naltrexona | |
| GEP20074208B (en) | Substituted amides active at the cannabinoid-1 receptor | |
| UA41346C2 (uk) | Фармацевтична композиція, яка містить флуоксетин або його сіль, таблетка на її основі, спосіб виробництва таблетки, яка диспергується | |
| PT845989E (pt) | Composicao de farmacos para aliviar a dor | |
| HRP20050253B1 (hr) | Diaril eteri kao opioid antagonisti opioidnih receptora | |
| ATE464049T1 (de) | Pharmazeutische kombinationen von hydrocodon und naltrexon | |
| HUP0204163A2 (hu) | Opioid agonistát és antagonistát tartalmazó szabályozott leadású készítmény és eljárás az előállítására | |
| EP0871488A4 (de) | Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu-opioidanagonisten und eines kappa - 2- opioidanagonisten | |
| CY1106927T1 (el) | Φαρμακευτικη συνθεση ενος pde4 ή pde3/4 αναστολεα και ανταγωνιστη υποδοχεα ισταμινης | |
| ES2198196A1 (es) | Composiciones topicas que comprenden un analgesico opioide y un antagonista de nmda. | |
| US20040092541A1 (en) | Synergistic combinations including n-acylated 4-hydroyphenylamine derivatives | |
| IL160272A0 (en) | Pharmaceutical compositions containing a pde4 or a pde3/4 inhibitor and a leukotriene receptor antagonist | |
| US9707225B2 (en) | Combinations of opioid/TLR4 antagonist and acetyl-para-aminophenol (APAP) for use in the treatment of pain | |
| MXPA05011476A (es) | Imidazolin-2-il-aminofenil-amidas como antagonistas de prostaglandina i2. | |
| EE03205B1 (et) | Ropivakaiini kasutamine valuvaigistina kasutatava ravimpreparaadi valmistamiseks | |
| ATE420860T1 (de) | N-substituierte amide als nk1 rezeptor antagonisten | |
| TW200505504A (en) | Saquinavir mesylate oral dosage form | |
| MX2008001608A (es) | Piperazinas acetilenicas como antagonistas de receptor de glutamato metabotropico. | |
| MX2008001607A (es) | Piperazinas biciclicas como antagonistas del receptor de glutamato metabotropico. | |
| WO2004041154A3 (en) | Abuse-resistant opioid dosage form | |
| HRP20090225T1 (hr) | Farmaceutske kompozicije na bazi nk2 antagonista za pedijatrijsku primjenu | |
| EA200401617A1 (ru) | Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера | |
| BR0212254A (pt) | Composição farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1562566 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |